Danaher Corp (DHR) Stock Price, Quote & News

Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell cultu...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 202 828 0850

Fax: 202 828 0860

Website: www.danaher.com

Address:

2200 Pennsylvania Avenue N.W., Suite 800W, Washington, United States

TalkMarkets May. 28 at 10:30 PM

Home Builders Could Drop 15% $TOL $ITB $SPY $DHR $TMO https://talkmarkets.com/article/home-builders-could-drop-15-1780007381

0 · Reply

cubie May. 28 at 7:26 PM

$A $DHR $TMO congrats bio equipment giddy bulls🫡😅

2 · Reply

11thestate May. 22 at 2:08 PM

When we see a stock like this, we know how many damaged investors are out there. Believe it or not, there’s some good news. $DHR investors you might be surprised, but you actually have a chance to recover your losses. Don’t miss it: https://11th.com/cases/danaher-investor-settlement

0 · Reply

Xen_TorpedoCapital May. 22 at 6:08 AM

$DHR $CSX $ARM Update May 22nd For today's run, Arm Holdings plc (ARM which is third engine, check separate post for today) is now supporting both Danaher Corporation (DHR) and CSX Corporation (CSX). This reinforces the existing setups and suggests a continued breakout move may be imminent.

0 · Reply

BillionerOfKing May. 21 at 7:32 PM

$DHR Current Stock Price: $173.32 Contracts to trade: $172.5 DHR May 22 2026 Call Entry: $1.45 Exit: $2.85 ROI: 96% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Xen_TorpedoCapital May. 21 at 7:09 AM

My latest run across the top 220 market cap stocks. Two names stood out based on recent data. Both appeared in yesterday's run (using day-before-yesterday's data), and there are no new signals from today's update. $DHR — Danaher Corporation Conditional on $CIEN performance. Currently showing resistance, but still has breakout potential. I would treat this as a HOLD for now. $CSX — CSX Corporation Conditional on $DELL performance. This setup appears fully bullish.

0 · Reply

STOCKPICKERTRADER May. 20 at 4:31 PM

$BSX BTD on these as equipment sector in healthcare only getting started imo. $MDT $BDX $DHR $IHI

0 · Reply

CapitalMonk May. 19 at 1:39 AM

$DHR Price: $163.86 (+1.20%) Trend: Bearish Market Bias (7D): Bullish Bias 📈 Expected Range: ±2.55% RSI: 16.5 | Momentum: Moderate Volume: -50.1% vs avg Volatility: 1.66% Support: $160.93 | Resistance: $200.50 Sourch: http://marketbaubles.com/

0 · Reply

accretivewealth May. 15 at 2:19 PM

$DHR Apparently, there is no bottom. Sometimes the market sends a message. Management does not always listen.

1 · Reply

accretivewealth May. 14 at 6:56 PM

$DHR worse than paint drying, paint peeling here

0 · Reply

Danaher resumed with a Buy at Citi

May 15, 2026, 1:00 AM EDT - 16 days ago

Even a High-Priced Market Has Bargains. 10 Undervalued Blue-Chip Stocks.

ABT ACN HD MCD MDT MKC RSG

2026-05-14T20:49:09.000Z - 17 days ago

Danaher resumed with an Outperform at RBC Capital

May 13, 2026, 2:20 PM EDT - 18 days ago

Danaher Transcript: Bank of America Global Healthcare Conference 2026

May 6, 2026, 4:15 PM EDT - 25 days ago

Danaher to Present at Bank of America Securities Healthcare Conference

May 5, 2026, 4:30 PM EDT - 26 days ago

Danaher Announces Quarterly Dividend

May 5, 2026, 3:00 PM EDT - 26 days ago

Danaher Transcript: AGM 2026

2026-05-04T13:40:51.000Z - 27 days ago

Masimo shareholders approve acquisition by Danaher

MASI

May 4, 2026, 9:00 AM EDT - 27 days ago

Masimo Shareholders Approve Acquisition by Danaher

MASI

2026-05-04T12:32:30.000Z - 27 days ago

Agilent appoints Michael Buckner as CLO

Apr 23, 2026, 1:39 PM EDT - 5 weeks ago

Danaher reaches $172.5 million settlement with shareholders over post-pandemic outlook

Apr 22, 2026, 7:15 PM EDT - 5 weeks ago

Danaher Announces Pricing of Euro-Denominated Senior Notes Offering

2026-04-22T13:48:48.000Z - 5 weeks ago

Danaher price target lowered to $250 from $270 at UBS

2026-04-22T11:24:15.000Z - 5 weeks ago

Danaher price target lowered to $245 from $249 at Baird

2026-04-22T11:18:47.000Z - 5 weeks ago

Danaher price target lowered to $235 from $275 at Guggenheim

2026-04-21T18:11:29.000Z - 5 weeks ago

Danaher price target raised to $245 from $240 at Jefferies

Apr 21, 2026, 8:00 AM EDT - 5 weeks ago

Danaher Earnings Call Transcript: Q1 2026

Apr 21, 2026, 8:00 AM EDT - 5 weeks ago

Danaher Earnings release: Q1 2026

Apr 21, 2026, 8:00 AM EDT - 5 weeks ago

Danaher Quarterly report: Q1 2026

Apr 21, 2026, 8:00 AM EDT - 5 weeks ago

Danaher Slides: Q1 2026

Apr 21, 2026, 7:33 AM EDT - 5 weeks ago

Danaher Lifts Full-Year Forecast on Biotech, Life Sciences Gains

Apr 21, 2026, 7:28 AM EDT - 5 weeks ago

Danaher beats first-quarter profit estimates on strong bioprocessing demand

2026-04-21T10:09:06.000Z - 5 weeks ago

Danaher reports Q1 adjusted EPS $2.06, consensus $1.94

2026-04-21T10:07:41.000Z - 5 weeks ago

Danaher sees Q2 non-GAAP core revenue up in LSD percentage range y/y

2026-04-21T10:06:16.000Z - 5 weeks ago

Danaher raises FY26 adjusted EPS view to $8.35-$8.55 from $8.35-$8.50

Apr 21, 2026, 6:00 AM EDT - 5 weeks ago

Danaher Reports First Quarter 2026 Results

2026-04-17T10:46:47.000Z - 6 weeks ago

Danaher price target lowered to $249 from $251 at Baird

2026-04-17T08:50:13.000Z - 6 weeks ago

Danaher price target lowered to $205 from $220 at Rothschild & Co Redburn

2026-04-14T10:49:13.000Z - 6 weeks ago

Danaher price target lowered to $230 from $250 at Barclays

Apr 13, 2026, 3:01 AM EDT - 6 weeks ago

Beckman Coulter Diagnostics Earns CE Mark for New Assay Delivering Bacterial vs. Viral Infection Results in Approximately 20 Minutes

Apr 9, 2026, 6:50 PM EDT - 7 weeks ago

Did Danaher Corporation Insiders Breach their Fiduciary Duties to Shareholders?

2026-04-06T12:01:15.000Z - 7 weeks ago

Danaher price target lowered, added to ‘Tactical Outperform’ list at Evercore

Mar 25, 2026, 8:00 AM EDT - 2 months ago

Danaher Proxy statement: Proxy filing

Mar 25, 2026, 8:00 AM EDT - 2 months ago

Danaher Proxy statement: Proxy filing

Mar 20, 2026, 4:15 PM EDT - 2 months ago

Danaher Schedules First Quarter 2026 Earnings Conference Call

Mar 3, 2026, 1:50 PM EST - 3 months ago

Danaher Transcript: TD Cowen 46th Annual Health Care Conference

Feb 26, 2026, 7:00 AM EST - 3 months ago

Danaher Slides: Corporate presentation

Feb 24, 2026, 4:05 PM EST - 3 months ago

Danaher to Present at TD Cowen Health Care Conference

Feb 17, 2026, 8:04 AM EST - 3 months ago

Danaher to buy Masimo for $9.9 billion

MASI

Feb 17, 2026, 8:02 AM EST - 3 months ago

Masimo to be Acquired by Danaher for $180.00 Per Share

MASI

Feb 17, 2026, 8:00 AM EST - 3 months ago

Danaher To Acquire Masimo Corporation

MASI

Feb 17, 2026, 6:09 AM EST - 3 months ago

Danaher Strikes $10 Billion Deal for Masimo

MASI

Feb 16, 2026, 11:11 PM EST - 3 months ago

Danaher closes in on nearly $10 billion deal for Masimo, FT reports

MASI

Feb 12, 2026, 12:30 PM EST - 3 months ago

Halper Sadeh LLC Encourages Danaher Corporation Shareholders to Contact the Firm to Discuss Their Rights

Jan 28, 2026, 8:00 AM EST - 4 months ago

Danaher Earnings Call Transcript: Q4 2025

Jan 28, 2026, 8:00 AM EST - 4 months ago

Danaher Annual report: Q4 2025

Jan 28, 2026, 8:00 AM EST - 4 months ago

Danaher Earnings release: Q4 2025

Jan 28, 2026, 8:00 AM EST - 4 months ago

Danaher Slides: Q4 2025

Jan 28, 2026, 7:08 AM EST - 4 months ago

Danaher forecasts 2026 profit in line with estimates on pharma spending recovery

Jan 28, 2026, 6:00 AM EST - 4 months ago

Danaher Reports Fourth Quarter and Full Year 2025 Results

Jan 13, 2026, 2:15 PM EST - 4 months ago

Danaher Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 2:15 PM EST - 4 months ago

Danaher Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 9:00 AM EST - 4 months ago

Danaher CEO to Comment on Financial Performance

Jan 8, 2026, 1:05 PM EST - 5 months ago

The Big 3: BA, DHR, DG

BA DG

Jan 8, 2026, 8:00 AM EST - 5 months ago

Danaher Is Ready to Put Its Post-Covid Malaise Behind It

Jan 5, 2026, 4:15 PM EST - 5 months ago

Danaher to Present at J.P. Morgan Healthcare Conference

Dec 24, 2025, 11:48 AM EST - 5 months ago

HALPER SADEH LLC ENCOURAGES DANAHER CORPORATION SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Dec 17, 2025, 7:30 AM EST - 5 months ago

Danaher Schedules Fourth Quarter 2025 Earnings Conference Call

Dec 4, 2025, 12:15 PM EST - 6 months ago

6 Dividend Stocks Ready To Benefit From 2026's Rate-Shift Economy

DX HSY NLY BMEZ UTG

Nov 18, 2025, 4:29 PM EST - 6 months ago

3 More Good Stocks to Invest In After Earnings

FTNT LPLA

Nov 18, 2025, 6:00 AM EST - 6 months ago

Danaher Transcript: Jefferies London Healthcare Conference 2025

Nov 13, 2025, 12:50 PM EST - 7 months ago

The Big 3: TMO, DHR, VLO

TMO VLO

Nov 11, 2025, 4:15 PM EST - 7 months ago

Danaher to Present at Jefferies Global Healthcare Conference

Oct 21, 2025, 10:55 AM EDT - 7 months ago

Is Danaher's Q3 beat enough to reignite long-term growth for DHR investors?

Oct 21, 2025, 8:00 AM EDT - 7 months ago

Danaher Earnings Call Transcript: Q3 2025

Oct 21, 2025, 8:00 AM EDT - 7 months ago

Danaher Quarterly report: Q3 2025

Oct 21, 2025, 8:00 AM EDT - 7 months ago

Danaher Earnings release: Q3 2025

Oct 21, 2025, 8:00 AM EDT - 7 months ago

Danaher Slides: Q3 2025

Oct 21, 2025, 7:01 AM EDT - 7 months ago

Danaher beats quarterly estimates on strength in diagnostic tools and tech

Oct 21, 2025, 6:23 AM EDT - 7 months ago

Danaher Sales and Profit Rise on Bioprocessing Momentum

Oct 21, 2025, 6:00 AM EDT - 7 months ago

Danaher Reports Third Quarter 2025 Results

Oct 15, 2025, 10:25 AM EDT - 8 months ago

Danaher Stock: Monopoly Margins, Discounted Price

Oct 6, 2025, 2:45 PM EDT - 8 months ago

4 Stocks That Aren't Too Hot to Buy Right Now

EVRG KNTK PWR XLU

Sep 23, 2025, 4:15 PM EDT - 8 months ago

Danaher Schedules Third Quarter 2025 Earnings Conference Call

Sep 11, 2025, 2:26 PM EDT - 9 months ago

Analysts' Top S&P 500 Stocks to Buy Now

HWM SPGI

Sep 10, 2025, 8:31 AM EDT - 9 months ago

Beckman Coulter Diagnostics Launches Industry First Fully Automated, High Throughput BD-Tau Research Use Only Immunoassay Test, Advancing Neurodegenerative Clinical Research

Jul 31, 2025, 4:15 PM EDT - 10 months ago

Danaher Appoints Jonathan Leiken as General Counsel

Jul 24, 2025, 8:08 PM EDT - 11 months ago

Investors decided the good outweighs the bad with Danaher, says Jim Cramer

TalkMarkets May. 28 at 10:30 PM

Home Builders Could Drop 15% $TOL $ITB $SPY $DHR $TMO https://talkmarkets.com/article/home-builders-could-drop-15-1780007381

0 · Reply

cubie May. 28 at 7:26 PM

$A $DHR $TMO congrats bio equipment giddy bulls🫡😅

2 · Reply

11thestate May. 22 at 2:08 PM

0 · Reply

Xen_TorpedoCapital May. 22 at 6:08 AM

0 · Reply

BillionerOfKing May. 21 at 7:32 PM

0 · Reply

Xen_TorpedoCapital May. 21 at 7:09 AM

0 · Reply

STOCKPICKERTRADER May. 20 at 4:31 PM

$BSX BTD on these as equipment sector in healthcare only getting started imo. $MDT $BDX $DHR $IHI

0 · Reply

CapitalMonk May. 19 at 1:39 AM

0 · Reply

accretivewealth May. 15 at 2:19 PM

$DHR Apparently, there is no bottom. Sometimes the market sends a message. Management does not always listen.

1 · Reply

accretivewealth May. 14 at 6:56 PM

$DHR worse than paint drying, paint peeling here

0 · Reply

Wallstfan May. 14 at 5:58 PM

$DHR here we go again, selling off back to red

0 · Reply

11thestate May. 14 at 2:33 PM

$DHR — Danaher Corporation Agreed to Settle With Investors Danaher Corporation has agreed to settle $172.5 million with investors regarding its bioprocessing business, COVID-related demand assumptions, and repeated guidance cuts. The agreement has already been submitted to the court for final approval. The settlement aims to compensate affected shareholders. If you purchased $DHR between January 27, 2022, and October 23, 2023, you may be eligible to file a claim and recover part of your losses. You can review the details and submit your claim here: https://11th.com/cases/danaher-investor-settlement

2 · Reply

Wallstfan May. 14 at 1:00 PM

$DHR great company on sale. If it’s not tech there just selling everything. At some point the rotation will come. Slowly taking a position here.

1 · Reply

dka79 May. 14 at 11:51 AM

$DHR reversal coming ?

1 · Reply

HedgeFollow May. 14 at 11:23 AM

🔍 𝗡𝗲𝘄 13𝗙 𝗥𝗲𝗹𝗲𝗮𝘀𝗲𝗱 🔎 Outstanding Hedge Fund Manager Alex Klabin of Senator Group made some Notable trades in Q1: 𝗡𝗲𝘄 Large 𝗕𝘂𝘆𝘀: $COP, $AMAT, $HAS 𝗗𝗢𝗨𝗕𝗟𝗘𝗗 position: $DHR 𝗦𝗢𝗟𝗗 out: $BILL Alex's portfolio is up 115.97% in the past 3 years. Source: https://hedgefollow.com/funds/Senator+Investment+Group

0 · Reply

peloswing May. 13 at 3:39 PM

Someone Just Bought the Dip on $DHR $1.5 Million of September $185 Calls AT THE ASK!

0 · Reply

TheStockTraderHub May. 13 at 3:33 PM

$DHR long dated CALL BUYER spotted 🐂

0 · Reply

accretivewealth May. 13 at 2:47 PM

$DHR There's Oversold, and then there's $DHR. Good night nurse!

0 · Reply

briefingcom May. 13 at 12:37 PM

$DHR: Danaher unit Cepheid receives IVDR CE mark for multiplex gastrointestinal test panel https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260513041937DHR&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

0 · Reply

DosGatos May. 12 at 5:46 PM

$DHR Execs & Upper Mgmt should be put on a PIP!

1 · Reply

Quant73 May. 12 at 4:14 PM

$ISRG Great breakdown of whats happening with $IHI stocks on Griffonomics. $WAT $DHR $SYK Very Bullish for $ISRG https://www.youtube.com/watch?v=7jv0vDOmlV8

0 · Reply

SuperGreenToday May. 12 at 3:57 PM

$DHR Share Price: $167.16 Contract Selected: Jun 05, 2026 $175 Calls Buy Zone: $1.87 – $2.31 Target Zone: $3.52 – $4.30 Potential Upside: 78% ROI Time to Expiration: 23 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Market Cap	129.29B
Revenue (ttm)	24.57B
Net Income (ttm)	3.61B
EPS (ttm)	N/A
PE Ratio	22.64
Forward PE	21.42
Profit Margin	14.71%
Debt to Equity Ratio	0.33

Volume	6,993,100
Avg Vol	4,690,446
Day's Range	N/A - N/A
Shares Out	707.77M
Stochastic %K	93%
Beta	0.81
Analysts	Strong Sell
Price Target	$242.57